CBD vs. cannabis: can a compound in weed help you use less?

NCT ID NCT06575751

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether cannabidiol (CBD), a non-psychoactive compound from cannabis, can reduce cannabis concentrate use and cravings in people who use concentrates regularly but aren't trying to stop. 120 participants will take either 200 mg or 400 mg of CBD or a placebo daily for 4 weeks. Researchers will measure changes in cannabis use, blood THC levels, and subjective effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Broad Spectrum Cannabidiol (bsCBD)
What this could lead to: If it works, this could point toward a treatment to help people who use cannabis concentrates cut back without having to quit entirely.
What could go wrong: This is an early Phase 2 trial with only 120 people, so results may not apply broadly. CBD might not reduce use or cravings more than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANNABIS USE DISORDER

Contacts and locations

Locations

University of Colorado Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.